Mesoblast (MESO) News
NASDAQ: MESOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
10.89-0.29 (-2.59%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MESO news summary
We found 10 recent headlines mentioning Mesoblast (MESO): 3 in the past week and 9 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, MESO is down 2.59% at $10.89. The most recent story, "Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award", was published by GlobeNewswire on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Mesoblast headlines
- Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth AwardNEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received the…GlobeNewswire
- Mesoblast Limited Announces Appointment of Jon Voigtman as Director on 10 November 2026Mesoblast Limited reported that Jon Voigtman was appointed as a director of the company on 10 November 2026. The appointment was disclosed in an Appendix 3X Initial Director's Interest Notice filed…NasdaqMESO, BIO.B
- Mesoblast Showcased at ASX Premier Investor Day EventNEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at…GlobeNewswire
- Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader WebinarNEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion…GlobeNewswire
- Mesoblast Limited Announces Board Retirements and Committee Leadership Changes Ahead of 2026 Annual General MeetingMesoblast Limited announced rotational changes and the retirement of certain members of its Board. After 12 years of serving on the Board since 2014, Mr William Burns will retire from the Board at…Nasdaq
- Mesoblast Board ChangesNEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and…GlobeNewswire
- Healthcare Stocks Rise: GKOS Surges 33%, TDOC Gains 30%, BHC Advances 26%, MESO Jumps Over 16%(RTTNews) - Shares of several healthcare companies moved higher following quarterly financial results and business updates. Glaukos raised its 2026 sales guidance and issued a preliminary outlook for…NasdaqBHC, GKOS, MESO, TDOC
- Mesoblast Limited Reports first quarter FY2027 Activity with 44% increase in net revenuesMesoblast Limited provided its activity report for the first fiscal quarter ended September 30, 2026. Financial highlights included a 44% increase in net revenues and an 86% improvement in net…Nasdaq
- Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for…GlobeNewswire
- RSI Alert: Mesoblast (MESO) Now OversoldLegendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq